Catalyst Pharmaceuticals Chief Legal Officer Disposes of Common Stock in Angelini Pharma Acquisition

Acquisition Completion and Merger Mechanics

The filing indicates that Catalyst Pharmaceuticals completed its acquisition by Angelini Pharma S.p.A. on July 15, 2026. This development represents a major corporate event for the pharmaceutical company, resulting in a change of control. The transaction mechanics established by the merger agreement dictated how equity securities held by company insiders would be handled at closing. Brian Elsbernd's disposition of 242,501 common shares at $31.50 per share occurred as a direct result of this merger consummation, suggesting that the acquisition price for CPRX common stock was set at $31.50 per share.

The filing documentation shows that the merger agreement included specific provisions for converting equity-based compensation instruments into cash payments. This approach, commonly referred to as "cash-out" mechanics, eliminated ongoing equity ownership and provided acquiring company certainty regarding the total cash consideration required to complete the transaction. For Elsbernd, the disposition of common stock and conversion of equity awards meant that his future economic interest in Catalyst Pharmaceuticals would be satisfied through cash payments rather than continued equity ownership.

Stock Options Converted to Cash Payment Rights

The disclosure reveals that Elsbernd held substantial stock option positions across multiple vesting schedules and exercise prices. According to the filing, he held options to purchase 132,000 shares at $4.64 per share, 200,000 shares at $3.42 per share, 135,000 shares at $7.07 per share, 69,000 shares at $18.59 per share, 147,621 shares at $14.15 per share, 126,704 shares at $21.12 per share, and 98,652 shares at $22.77 per share. The filing states that these options ranged in vesting dates from December 2, 2026, through November 20, 2032. All of these options became fully vested upon the merger's consummation.

Under the merger agreement's conversion mechanism detailed in the filing, each stock option was cancelled and converted into a right to receive a cash payment calculated as the merger consideration of $31.50 per share minus the exercise price of the option, multiplied by the number of shares subject to that option. This conversion meant that Elsbernd received economic value from all his option positions, regardless of whether those options had been in-the-money or out-of-the-money before the transaction. The filing indicates that these cash payments are subject to applicable tax withholdings and other authorized deductions, a standard provision in acquisition transactions.

Restricted Stock Units Converted Following Merger Close

In addition to common stock and stock options, Elsbernd held restricted stock units that were affected by the merger. The filing discloses that he held 7,067 restricted stock units vesting on December 8, 2026, 10,322 restricted stock units vesting on November 21, 2027, and 29,776 restricted stock units vesting on November 20, 2028. The filing states that each restricted stock unit represents a contingent right to receive one share of Catalyst Pharmaceuticals common stock, and that all of these units vested in full upon the merger's consummation.

Like the stock options, the restricted stock units were cancelled and converted into cash payment rights under the merger agreement. The conversion formula applied to RSUs was simpler than that for options: each RSU was converted into a right to receive a cash payment equal to $31.50 per share multiplied by the number of shares subject to that RSU. This treatment meant that RSU holders effectively received the full merger consideration per unit, without reduction for any exercise price. The filing indicates that all such payments remain subject to applicable tax withholdings and authorized deductions.

Elsbernd's Executive Role and Beneficial Ownership

The filing confirms that Brian Elsbernd held the position of Chief Legal Officer at Catalyst Pharmaceuticals and was subject to Section 16 reporting obligations as a company officer. His insider filing status required disclosure of his transactions and beneficial ownership positions to the Securities and Exchange Commission. Prior to the merger consummation, Elsbernd's beneficial ownership included both direct holdings of common stock and equity-based awards that carried contingent rights to obtain company shares or cash equivalents.

The filing does not disclose Elsbernd's total beneficial ownership position in the company before the merger transaction or provide details regarding his current beneficial ownership status following the disposition and conversion events. Investors reviewing the disclosure would note that his holdings represented a significant equity stake in the company, as evidenced by the substantial number of option grants and RSUs accumulated across multiple years of service. The variety of exercise prices and vesting dates reflects typical equity grant practices for executive compensation over an extended employment period.

Transaction Details and Filing Timeline

The filing was executed on July 17, 2026, two days after the transaction date of July 15, 2026, representing a standard filing timeline for insider transaction disclosures. The earliest transaction date reported in the filing is July 15, 2026, which corresponds to the closing date of the Angelini Pharma acquisition. The filing is structured as a single-reporting-person submission, indicating that Elsbernd filed this disclosure independently rather than as part of a joint filing with other insiders.

All transactions reported in the filing are coded as Code "D" for dispositions of securities in Table I (common stock) and derivative securities held in Table II (options and RSUs). The filing indicates that all common stock dispositions were direct transactions, and all options and RSUs were directly held by Elsbernd. No indirect beneficial ownership through trusts, family members, or other entities is disclosed for any of the reported securities. The documentation includes Elsbernd's certification by signature, affirming the accuracy and completeness of the information provided.

Cash Consideration and Pricing Framework

The merger consideration of $31.50 per share established the baseline for calculating cash payments to holders of equity securities, as disclosed in the filing. For Elsbernd's 242,501 common shares disposed of on July 15, 2026, this price point represented the value received for his direct equity ownership. For his stock options, the intrinsic value at the merger consideration—the spread between $31.50 and each option's exercise price—determined the cash payment amount. Options with lower exercise prices, such as those at $3.42 and $4.64 per share, carried substantially greater cash values than those with higher exercise prices.

The filing's explanation section specifies that all cash payments are made "without interest, and less applicable tax withholdings and other authorized deductions." This standard language in merger documentation indicates that shareholders and optionholders do not receive interest accruals on their merger consideration, and that transaction proceeds are subject to federal, state, and potentially local tax withholding obligations. The specific dollar amounts of cash payments to Elsbernd for his options and RSUs are not disclosed in this filing; those amounts would be calculated according to the merger agreement's conversion formulas applied to his individual holdings.

Vesting Acceleration Upon Merger Consummation

A significant aspect of the merger agreement reflected in the filing is the full acceleration of vesting for all equity awards upon the transaction's consummation. The filing explicitly states that each option and RSU "vested in full in connection with the consummation of the Merger." This provision meant that equity awards with future vesting schedules—including options not scheduled to vest until December 2032 and RSUs with 2027 and 2028 vesting dates—immediately became vested and eligible for conversion to cash payments.

This vesting acceleration is a common protective provision for employees in change-of-control transactions, designed to ensure that employees receive the economic value of their equity awards regardless of how many additional years they were originally scheduled to vest over. For Elsbernd, whose most recently granted options did not vest until 2032 and whose longest-dated RSU vested in 2028, the acceleration provision converted these time-contingent awards into current cash payment obligations. The filing does not disclose the aggregate dollar value of the conversion payments Elsbernd received or will receive from all his equity awards combined.

Regulatory Compliance and Insider Disclosure Requirements

The Form 4 filing represents Catalyst Pharmaceuticals' and Elsbernd's compliance with Section 16 of the Securities Exchange Act of 1934, which requires officers, directors, and ten-percent beneficial owners to report changes in beneficial ownership within two business days of the transaction. The filing includes all required tables documenting non-derivative securities (common stock) and derivative securities (options and RSUs), along with explanatory notes specifying the merger transaction's effect on each security class held by Elsbernd.

The filing header indicates the estimated average burden hours per Form 4 response as 0.5 hours and references OMB Number 3235-0287 for information collection purposes. The document includes a standard reminder that intentional misstatements or omissions of facts constitute federal criminal violations under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a). These regulatory requirements and penalties underscore the legal obligation for accurate and complete disclosure of insider transactions and beneficial ownership positions by company officers subject to Section 16 reporting obligations.

What Investors Should Note About the Acquisition Completion

The Form 4 filing provides concrete evidence that Catalyst Pharmaceuticals' acquisition by Angelini Pharma S.p.A. was completed and closed as of July 15, 2026. The transaction resulted in Catalyst stockholders and equity award holders receiving the $31.50 per share merger consideration in accordance with the merger agreement's terms. For investors who held CPRX shares before the closing, this filing confirms the final pricing and transaction completion, though it does not provide broader context regarding Angelini Pharma's strategic rationale or post-acquisition plans for the combined company.

The disclosure of Elsbernd's equity dispositions and conversions indicates that company insiders benefited materially from the merger transaction. The conversion of options with exercise prices substantially below the $31.50 merger consideration—particularly the 200,000 options at $3.42 per share and 132,000 options at $4.64 per share—would have generated significant intrinsic value for Elsbernd upon conversion. However, the filing does not quantify these amounts or provide information about other executives' stakes in the transaction, limiting investors' ability to assess the total economic impact on company leadership.